KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deferred Tax Liability: 2015-2025

Historic Non-Current Deferred Tax Liability for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Mar 2025 value amounting to $981,000.

  • Supernus Pharmaceuticals' Non-Current Deferred Tax Liability fell 94.97% to $981,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $981,000, marking a year-over-year decrease of 94.97%. This contributed to the annual value of $5.0 million for FY2024, which is 96.83% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non-Current Deferred Tax Liability of $981,000 as of Q1 2025, which was down 80.23% from $5.0 million recorded in Q4 2024.
  • In the past 5 years, Supernus Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $229.6 million in Q4 2021 and a low of $981,000 during Q1 2025.
  • For the 3-year period, Supernus Pharmaceuticals' Non-Current Deferred Tax Liability averaged around $36.6 million, with its median value being $19.5 million (2024).
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first surged by 97.98% in 2022, then slumped by 96.83% in 2024.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Non-Current Deferred Tax Liability stood at $229.6 million in 2021, then decreased by 19.58% to $184.7 million in 2022, then decreased by 15.39% to $156.3 million in 2023, then crashed by 96.83% to $5.0 million in 2024, then crashed by 94.97% to $981,000 in 2025.
  • Its last three reported values are $981,000 in Q1 2025, $5.0 million for Q4 2024, and $7.4 million during Q3 2024.